Oral antifungal fluconazole is "at least as effective and may be superior" to the standard treatment of I.V. amphotericin B in preventing recurrences of AIDS-related cryptococcal meningitis, HHS announced May 11. Conclusion was based on suspended U.S. multicenter trials of 205 patients conducted by Pfizer, the National Institute for Allergy and Infectious Disease AIDS Clinical Trials Group and its Mycoses Study Group. NIAID, based on preliminary results of the study, now recommends that Diflucan replace amphotericin B (Bristol-Myers Squibb's Fungizone) for the recurrence prevention treatment. Diflucan, in oral and I.V. forms, was approved Jan. 29 ("The Pink Sheet" Feb. 5, p. 5).
You may also be interested in...
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.